Motif Bio PLC Iclaprim Clinical Trial Supplies Manufactured (0364J)

TIDMMTFB

RNS Number : 0364J

Motif Bio PLC

15 December 2015

Motif Bio plc

("Motif" or the "Company")

Iclaprim Clinical Trial Supplies Manufactured

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites. These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017.

Graham Lumsden, CEO, stated: "This is a major milestone for Motif given the complexity and costs usually associated with the manufacture of clinical trial supplies in sufficient quantity for large Phase III trials. We were able to utilise commercial-scale batches of the API (Active Pharmaceutical Ingredient) that we own as a result of our merger earlier this year with Nuprim Inc. This API, which we reprocessed to generate new material, has now been used to manufacture sterile ampoules for clinical trial supplies and we are on track to complete the trials in the second half 2017."

Enquiries:

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  www.motifbio.com 
 Zeus Capital Limited (NOMINATED 
  ADVISER and BROKER) 
  Phil Walker/Dan Bate                   +44 (0) 20 
  Dominic Wilson                          3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell        +44 (0) 20 
  John Howes/ Mark Treharne (Broking)     7382 1100 
 
 
                                           +49 (0) 89 
   MC Services AG (TRADE PR)               210 2280 
   Raimund Gabriel                         +44 (0) 207 
   Shaun Brown                             148 5998 
 Plumtree Capital Limited (FINANCIAL 
  ADVISOR)                               +44 (0) 207 
  Stephen Austin                          183 2493 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Charles Goodwin                        +44 (0) 7747 
  Dominic Barretto                        788 221

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGGWPPUPAPPC

(END) Dow Jones Newswires

December 15, 2015 02:00 ET (07:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024